Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the stocks with explosive growth potential. On February 23, Summit Therapeutics reported results for 2025 with a strong financial foundation, reporting ~$713.4 million in cash and no outstanding debt. While GAAP operating expenses for Q4 reached $225 million, this represented a decrease from the previous quarter. Conversely, non-GAAP operating expenses rose to $113.3 million as the company ramped up investment in its Harmony 3 and Harmony 7 clinical trials.

The company’s focus remains on the development of ivonescimab, supported by a pipeline of 15 Phase 3 trials and over 4,000 enrolled patients globally. A key highlight is the upcoming interim progression-free survival analysis for the Harmony 3 squamous lung cancer cohort, expected in Q2 2026. Summit also expanded its therapeutic reach through high-profile clinical collaborations, including a partnership with GSK to evaluate ivonescimab alongside a novel antibody-drug conjugate and a collaboration with Revolution Medicines to test combinations with RAS inhibitors across various solid tumors.

Despite these advancements, Summit Therapeutics Inc. (NASDAQ:SMMT) faces regulatory hurdles, as the FDA emphasized that statistically significant overall survival data is required for marketing authorization in certain lung cancer indications. Because overall survival data for the Harmony 3 study will remain immature during the upcoming interim PFS readout, there is inherent uncertainty regarding the timeline for regulatory approval.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and society-friendly medicinal therapies.

While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Stocks for Beginners with Little Money in 2026.

Disclosure: None. Follow Insider Monkey on Google News.